Phoenix-based cancer research nonprofit awarded $4.5 million grant
City of Hope, TGen look to advance liquid biopsy for pancreatic cancer early detection
Special to Independent Newsmedia
Posted 10/29/23
City of Hope, one of the largest cancer research and treatment organizations in the U.S., and Phoenix-based TGen were awarded a five-year, $4.5 million grant to advance liquid biopsy for pancreatic cancer.
You must be a member to read this story.
Join our family of readers for as little as $5 per month and support local, unbiased journalism.
Current print subscribers can create a free account by clicking here
Otherwise, follow the link below to join.
To Our Valued Readers –
Visitors to our website will be limited to five stories per month unless they opt to subscribe. The five stories do not include our exclusive content written by our journalists.
For $6.99, less than 20 cents a day, digital subscribers will receive unlimited access to YourValley.net, including exclusive content from our newsroom and access to our Daily Independent e-edition.
Our commitment to balanced, fair reporting and local coverage provides insight and perspective not found anywhere else.
Your financial commitment will help to preserve the kind of honest journalism produced by our reporters and editors. We trust you agree that independent journalism is an essential component of our democracy. Please click here to subscribe.
Need to set up your free e-Newspaper all-access account? click here.
Non-subscribers
Click here to see your options for becoming a subscriber.
Register to comment
Click here create a free account for posting comments.
Note that free accounts do not include access to premium content on this site.
I am anchor
YOUR HEALTH
Phoenix-based cancer research nonprofit awarded $4.5 million grant
City of Hope, TGen look to advance liquid biopsy for pancreatic cancer early detection
(Metro Creative Connection)
Posted
Special to Independent Newsmedia
City of Hope, one of the largest cancer research and treatment organizations in the U.S., and Phoenix-based TGen were awarded a five-year, $4.5 million grant to advance liquid biopsy for pancreatic cancer.
The blood-based diagnostic developed by the National Cancer Institute’s Pancreatic Cancer Detection Consortium leverages exosomal microRNAs that serve as a biomarker or unique RNA fingerprint for the early detection of disease or recurrence.
Translational Genomics Research Institute (TGen), headquartered at 445 N. 5th St. in Phoenix, is a nonprofit dedicated to research with life-changing results. TGen is part of City of Hope, an independent research and treatment center for cancer, diabetes and other life-threatening diseases.
The National Institutes of Health’s National Cancer Institute awarded the $4.5 million grant to co-principal investigators Ajay Goel, chair of the Department of Molecular Diagnostics and Experimental Therapeutics at Beckman Research Institute of City of Hope, and Daniel D. Von Hoff, professor in the Molecular Medicine Division at Translational Genomics Research Institute (TGen).
“Biomarkers are like fingerprints of our health, offering invaluable insights without requiring invasive procedures,” Goel shared in a press release. “The biomarker signature we found is able to act as a text notification, allowing oncologists to detect and monitor pancreatic cancer in a noninvasive manner.”
The American Society of Clinical Oncology identifies pancreatic cancer as the fourth leading cause of cancer-related deaths among adults in the United States. PDAC (pancreatic ductal adenocarcinoma) is particularly deadly, with less than 6% of patients surviving for five or more years after diagnosis.
One of the main reasons for the high mortality rate of PDAC is the lack of reliable methods for diagnosing it at an early stage when medical treatment can make a significant difference. PDAC typically doesn’t show noticeable symptoms in the early stages, so the most practical approach to early diagnosis is to develop a screening tool that can be used by any doctor for any patient.
The consortium will validate the diagnostic and test its effectiveness in retrospective longitudinal cohorts to assess its utility, the press release notes. Initial data suggest confidence that the diagnostic can identify abnormal cell growth and cancer without requiring surgery.
If accurate, the novel diagnostic has the potential to reduce unnecessary surgeries and associated complications.
“We desperately need tools for very early detection of pancreatic cancer at stages where it can be treated effectively,” Von Hoff stated. “Our preliminary data are promising, and this grant will help solidify just how reliable this test will be.”